Washington -- The U.S. Food and Drug Administration has approved a new injectable drug, Treanda, for the treatment of chronic lymphocytic leukemia.
Pharmaceutical manufacturer Cephalon Inc. of Frazer, Pa., said Treanda (bendamustine hydrochloride) received priority review by the FDA and was approved within six months of the company's application.
Chronic lymphocytic leukemia, or CLL, is a slowly progressing blood and bone marrow disease. The American Cancer Society estimates more than 15,000 new cases of the rare disease will be diagnosed in the United States this year.
Cephalon officials said they anticipate Treanda will become available to physicians and patients as a CLL treatment in the United States next month.
Treanda has also been granted orphan drug status by the FDA, thereby providing Cephalon with marketing exclusivity until March 2015.
Disclaimer: The views and investment tips expressed by investment experts on themoneytimes.com are their own, and not that of the website or its management. TheMoneyTimes advises users to check with certified experts before taking any investment decision.
Recent comments
1 day 3 hours ago
1 day 9 hours ago
1 day 9 hours ago
1 day 12 hours ago
1 day 13 hours ago
2 days 6 hours ago
2 days 19 hours ago
4 days 4 hours ago
1 week 21 hours ago
1 week 1 day ago